Sars-CoV2: Clinical Trials

17 trials for Sars-CoV2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed. 17 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 217Completed 17
Phase 14Completed 4
Phase 31Completed 1

Follow Sars-CoV2: new trials by email Literature Review of Sars-CoV2 trials Research Report on Sars-CoV2

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
Mesenchymal Stromal Cells, Supportive Care - Sars-CoV2, Acute Respiratory Distress Syndrome
Phase 1 / Phase 2CompletedBaylor College of Medicine282021-02-122026-10-21
Methylene Blue Treatment of COVID-19
Methylene Blue, Control Test - SARS-CoV2
Phase 2CompletedFondazione Epatocentro Ticino292020-11-052025-08-17
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
LSALT peptide, Placebo - COVID, Severe Acute Respiratory Syndrome
Phase 2CompletedArch Biopartners Inc.612020-10-142025-07-09
Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease
N-acetylcysteine - COVID, Sars-CoV2
Phase 2CompletedCambridge Health Alliance1652020-09-232021-05-28
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
Mavrilimumab, Placebos - COVID-19, Sars-CoV2
Phase 2CompletedVirginia Commonwealth University22020-09-022021-08-11
Rhu-pGSN for Severe Covid-19 Pneumonia
Recombinant human plasma gelsolin (Rhu-pGSN), Placebo - Sars-CoV2
Phase 2CompletedBioAegis Therapeutics Inc.642020-07-302023-11-28
Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation
Vitamins, Telmisartan, Ciclesonide - Corona Virus Infection, Sars-CoV2
Phase 2 / Phase 3CompletedUniversity Hospital, Bordeaux4122020-07-292026-05-12
Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19
Favipiravir, Placebo, Standard of care treatment - Sars-CoV2, COVID-19
Phase 2CompletedStanford University1492020-07-122022-07-13
A Study of Quintuple Therapy to Treat COVID-19 Infection
Hydroxychloroquine, Azithromycin, Vitamin C - COVID-19, Corona Virus Infection
Phase 2CompletedProgenaBiome1182020-06-222024-02-29
A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection
Hydroxychloroquine, Vitamin C, Vitamin D - COVID-19, Coronavirus Infection
Phase 2CompletedProgenaBiome2542020-06-222026-11-04
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
COVID-19 Convalescent Plasma (CCP), Placebo - COVID-19, Sars-CoV2
Phase 2CompletedPriscilla Hsue, MD342020-06-092022-10-07
Using GM-CSF as a Host Directed Therapeutic Against COVID-19
Sargramostim, Normal Saline 0.9% - COVID, Sars-CoV2
Phase 2CompletedSingapore General Hospital22020-06-022022-05-10
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
APL-9, Vehicle Control - COVID, Covid-19
Phase 1 / Phase 2CompletedApellis Pharmaceuticals, Inc.722020-05-282022-03-23
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19
Peginterferon Lambda-1A, placebo - Sars-CoV2, Covid-19
Phase 2CompletedUniversity Health Network, Toronto1572020-05-132023-12-13
Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
Allogenic pooled olfactory mucosa-derived mesenchymal stem cells, Standard treatment according to the Clinical protocols - COVID, Covid-19
Phase 1 / Phase 2CompletedInstitute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus322020-05-112021-08-23
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
Viusid and Asbrip - Covid-19, Sars-CoV2
Phase 2CompletedCatalysis SL602020-05-042021-01-08
Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19
ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS - Sars-CoV2
Phase 1 / Phase 2CompletedAndalusian Network for Design and Translation of Advanced Therapies262020-04-272022-04-06

Narrower conditions

COVID-19 (13)  ·  Coronavirus Infections (5)  ·  Respiratory Distress Syndrome (4)  ·  Pneumonia (3)  ·  Severe Acute Respiratory Syndrome (2)  ·  Acute Kidney Injury (1)  ·  Acute Lung Injury (1)  ·  Cytokine Release Syndrome (1)  ·  Diabetes Mellitus (1)  ·  Heart Diseases (1)  ·  Kidney Diseases (1)  ·  Liver Diseases (1)  ·  Lung Diseases (1)  ·  Lung Diseases, Interstitial (1)  ·  Lymphoma, Follicular (1)

Broader conditions

Coronaviridae Infections (15)  ·  Infections (15)  ·  Nidovirales Infections (15)  ·  RNA Virus Infections (15)  ·  Virus Diseases (15)  ·  Respiratory Tract Diseases (14)  ·  Respiratory Tract Infections (14)  ·  Lung Diseases (13)  ·  Pneumonia, Viral (12)  ·  Coronavirus Infections (10)  ·  Pneumonia (10)  ·  Respiration Disorders (4)  ·  Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Male Urogenital Diseases (2)

Interventions

Ascorbic Acid (2)  ·  Hydroxychloroquine (2)  ·  Vitamin D (2)  ·  Zinc (2)  ·  Acetylcysteine (1)  ·  Azithromycin (1)  ·  COVID-19 Serotherapy (1)  ·  Colony-Stimulating Factors (1)  ·  Gelsolin (1)  ·  Granulocyte-Macrophage Colony-Stimulating Factor (1)  ·  Methylene Blue (1)  ·  Palliative Care (1)  ·  Saline Solution (1)  ·  Telmisartan (1)  ·  Vitamins (1)

Sponsors

ProgenaBiome (2)  ·  Andalusian Network for Design and Translation of Advanced Therapies (1)  ·  Apellis Pharmaceuticals, Inc. (1)  ·  Arch Biopartners Inc. (1)  ·  Baylor College of Medicine (1)  ·  BioAegis Therapeutics Inc. (1)  ·  Cambridge Health Alliance (1)  ·  Catalysis SL (1)  ·  Fondazione Epatocentro Ticino (1)  ·  Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus (1)  ·  Priscilla Hsue, MD (1)  ·  Singapore General Hospital (1)  ·  Stanford University (1)  ·  University Health Network, Toronto (1)  ·  University Hospital, Bordeaux (1)

Countries

United States (9)  ·  Brazil (2)  ·  Canada (2)  ·  Spain (2)  ·  Belarus (1)  ·  Ecuador (1)  ·  France (1)  ·  Romania (1)  ·  Singapore (1)  ·  Switzerland (1)  ·  Turkey (Türkiye) (1)

Top investigators

Sabine Hazan, MD (2)  ·  Andrei Y Hancharou, Dr. (1)  ·  Annie Leutkemeyer, MD (1)  ·  Antonio Abbate, MD, PhD (1)  ·  Eduard A Dotsenko, Dr., prof. (1)  ·  Helen Heslop, MD (1)  ·  Jenny Low, MBBS (1)  ·  Jordan Feld, MD (1)  ·  LaQuisa Hill, MD (1)  ·  Mark J DiNubile, MD (1)  ·  Natalia G Antonevich, Dr. (1)  ·  Priscilla Hsue, MD (1)

Results publications

PMID 32555385, PMID 32788708, PMID 33050924, PMID 33556319, PMID 33624010, PMID 33754144, PMID 34473343, PMID 35446944, PMID 38454482, PMID 38490660